The stock of Aurinia Pharmaceuticals Inc (AUPH) has gone down by -1.04% for the week, with a 5.87% rise in the past month and a 26.78% rise in the past quarter. The volatility ratio for the week is 3.47%, and the volatility levels for the past 30 days are 4.78% for AUPH. The simple moving average for the past 20 days is 2.76% for AUPH’s stock, with a 13.37% simple moving average for the past 200 days.
Is It Worth Investing in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Right Now?
The stock has a 36-month beta value of 1.44. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AUPH is 128.68M, and at present, short sellers hold a 5.89% of that float. On September 26, 2024, the average trading volume of AUPH was 1.43M shares.
AUPH) stock’s latest price update
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has experienced a decline in its stock price by -1.04 compared to its previous closing price of 7.20. However, the company has seen a fall of -1.04% in its stock price over the last five trading days. seekingalpha.com reported 2024-09-19 that Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the ‘Big Mo,’ indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at 13.64% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.10% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 3.47%, as shares surge +7.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.58% upper at present.
During the last 5 trading sessions, AUPH fell by -1.39%, which changed the moving average for the period of 200-days by -19.86% in comparison to the 20-day moving average, which settled at $6.96. In addition, Aurinia Pharmaceuticals Inc saw -20.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Habig Scott Michael, who sale 18,249 shares at the price of $5.31 back on Aug 06 ’24. After this action, Habig Scott Michael now owns 456,338 shares of Aurinia Pharmaceuticals Inc, valued at $96,902 using the latest closing price.
Balakrishnan Brinda, the Director of Aurinia Pharmaceuticals Inc, sale 520 shares at $5.74 during a trade that took place back on May 21 ’24, which means that Balakrishnan Brinda is holding 17,523 shares at $2,985 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.86 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -0.24. The total capital return value is set at -0.11. Equity return is now at value -13.30, with -9.39 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.01. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -9.3.
Currently, EBITDA for the company is -71.67 million with net debt to EBITDA at -2.2. When we switch over and look at the enterprise to sales, we see a ratio of 5.21. The receivables turnover for the company is 8.11for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.33.
Conclusion
To sum up, Aurinia Pharmaceuticals Inc (AUPH) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
